Company intelligence / Profile preview

Mars

Christchurch, Canterbury, New Zealandmars.com ↗

Ownership: Private
Development stage: Commercial

Overview

MARS Bioimaging has developed the world’s first commercial pre-clinical spectral CT scanner using Medipix3RX detectors. Their technology enables high-resolution molecular imaging with applications in cancer detection and development of new contrast agents. The company is preparing to launch a human extremity scanner for clinical use pending regulatory approvals.

Therapeutic areas: OncologyOther
Modalities: Device
Industry: Medical Imaging

Partnerships

CERN (Medipix collaboration)University of CanterburyUniversity of Otago

Beyond the preview

Go deeper on Mars.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mars.

Explore the full profile